Investors

Investor Area: Supporting Our Growth

In 2026, A.F. GENESE will reach a decisive milestone in its history with the completion of its first clinical study in collaboration with the Brain & Mind biocluster.

Following a successful initial fundraising round completed in August 2025 with Business Angels, we are now embarking on a new strategic phase.

A.F. GENESE is opening its capital for a SEED funding round to accelerate its R&D, regulatory, and clinical developments, while initiating its commercial ramp-up.

Why Invest in A.F. GENESE?

We offer the opportunity to participate in a high-potential technological venture, structured around four major pillars:
01.

Strong Competitive Advantages

  • Patented technology: Solid intellectual protection creating genuine barriers to entry.
  • Scientific validation: Efficacy already demonstrated in real-life settings and soon to be confirmed in our first clinical study.
  • Expertise: An experienced team. A successful initial product launch in the wellness sector (E-Tonus Program).
Read More
02.

Optimal Market Timing

  • Unmet needs: A rapidly growing market with strong demand for new solutions.
  • Strong support: Robust institutional backing, particularly from the Brain & Mind biocluster.
  • Favorable framework: Current regulations encourage the emergence of innovative devices.
Read More
03.

High Scale Potential

  • Scalable model: A recurring business model designed for rapid growth.
  • Geographical ambition: Prospects for expansion into new pathologies and geographical areas.
Read More
04.

Major Societal Impact

  • Quality of life: Concrete improvement in patients' daily lives.
  • Public health: A solution contributing to the reduction of healthcare costs.
  • Therapeutic innovation: A credible and effective alternative to heavy treatments.
Read More

Investors

Join the A.F. GENESE Adventure

We invite institutional investors, venture capital funds, and private investors to contact us for a detailed presentation of the A.F. GENESE project and to discuss our valuation prospects.

Investor Relations

Jean-Sébastien SUZE | Managing Director & Shareholder of Reference

Would you like more information about our vision or our development?

Please complete the form below. We will get back to you as soon as possible.

Error: Contact form not found.

Investors